Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported Depreciation & Amortization (CF) of $19000.0 for Q4 2025, down 76.54% on a YoY basis from $81000.0 in Q4 2024, and down 84.3% quarter-over-quarter from $121000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $19000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 76.54% year-over-year to $19000.0; the trailing twelve-month figure through Dec 2025 stood at $296000.0 (down 12.94% YoY), and the FY2025 full-year result was $296000.0, down 12.94% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $19000.0, down from $121000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $290000.0 in Q1 2023, with the low at $19000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $128800.0 across 5 years, with a median of $102000.0 in 2022.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 63.84% — and 2025, when it plunged 76.54%.
- Karyopharm Therapeutics' Depreciation & Amortization (CF) stood at $139000.0 in 2021, then retreated by 18.71% to $113000.0 in 2022, then tumbled by 31.86% to $77000.0 in 2023, then rose by 5.19% to $81000.0 in 2024, then tumbled by 76.54% to $19000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $19000.0 (Q4 2025), $121000.0 (Q3 2025), and $78000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 121,000.00 |
| Sep 30, 2025 | 121,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Sep 30, 2023 | 80,000.00 |